Merck Restricts Purchases of 340B Drugs for 340B Hospitals Effective September 1st, 2021

On August 11, Merck issued a letter announcing its policy to stop “voluntarily” providing 340B discounts to 340B hospitals on drugs dispensed at contract pharmacies unless the hospital provides 340B contract pharmacy claims data through the 340B ESPTM  platform for both Medicaid and non-Medicaid claims.  Merck joins seven other drug manufacturers that have adopted similar policies based on their…

Indiana District Court Holds Important Hearing on HRSA’s Enforcement and Eli Lilly’s 340B Price Restrictions

On July 30, the U.S. District Court for the Southern District of Indiana held oral arguments in the case, Eli Lilly et al. v. Becerra et al., regarding the May 17 enforcement letter (“May 17 Letter”) that HRSA sent to Eli Lilly and other drug manufacturers informing them of HRSA’s formal determination that their actions to…

House of Representatives Approves Spanberger-McKinley Amendment Supporting HRSA Action Against Drug Manufacturer

On July 27, the U.S. House of Representatives approved an amendment to the House Appropriations Labor, Health and Human Services legislation that supports agency action against manufacturers that are not honoring contract pharmacy arrangements.  The amendment was approved as part of a funding package for the next fiscal year for many federal departments, including HHS.  The…

On July 11, the U.S. House Appropriations Committee emphasizes the importance of the 340B program in HHS report

On July 11, the U.S. House Appropriations Committee approved the fiscal year (FY) 2022 appropriations bill (the “Bill”) and accompanying report for the Department of Labor, HHS, Education, and Related Agencies.  The accompanying report calls for HRSA to report on actions it is taking to (1) safeguard safety-net providers’ access to discounted drugs, including those dispensed at contract pharmacies, and…

Secretary of Health and Human Services (HHS) appoints of the much-awaited 340B Alternative Dispute Resolution (ADR) Board

340B Safety net providers laud the Secretary of Health and Human Services’ (HHS) appointment of the much-awaited 340B Alternative Dispute Resolution (ADR) Board on June 21, 2021.  Members of the ADR Board will serve as ADR Panelists to resolve disputes between 340B safety-net providers and drug companies. Beginning in the summer of 2020, several drug manufacturers have…

Secretary Becerra Provides Important Insight on 340B at the U.S. Senate Appropriations Sub-Committee

On June 9, 2021, U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra appeared before the U.S. Senate Appropriations subcommittee.  In his testimony, Secretary Becerra provided important insight into HHS’s stance regarding six drug companies’ unilateral actions to halt 340B pricing on drugs shipped to contract pharmacies.  Senator Manchin stated his interest in…

White House Budget Office Approves Plan to Rescind Controversial Trump-Era Insulin Rule

Earlier this week, the White House Office of Management and Budget (OMB) completed its review of HHS’ proposal to rescind the Trump Administration’s final rule that would require federally qualified health centers (FQHCs) to provide insulin and injectable epinephrine to low-income patients at the price the FQHC pays for those drugs under the 340B program.…

Tennessee Governor Enacts Law to Protect 340B Covered Entities from Discriminatory Reimbursement Practices

Last week, Tennessee Governor Bill Lee signed into a law a bill that will protect 340B covered entities and their contract pharmacies from discriminatory reimbursement practices commonly employed by pharmacy benefit managers (PBMs) and third party payers and will help to bring pricing transparency to Tennessee’s healthcare system (HB 1398/SB 1617).    The law prohibits…

CV340B’s Northeast Regional Advocacy Plans ‘340B in the Northeast’ Webinar for May 25th, 2021

CV340B’s Northeast Regional Advocacy Group is hosting a webinar titled ‘340B in the Northeast’ scheduled for 11:00am- 12:00pm on Tuesday May 25th, 2021. Webinar will include a brief history of the 340B Drug Pricing Program, current threats to the program, a panel of Northeastern providers and a discussion on advocacy. The panel will discuss how…